Literature DB >> 8352299

Clinical and immunologic features of human T-cell lymphotropic virus type I uveitis.

K Yoshimura1, M Mochizuki, S Araki, N Miyata, K Yamaguchi, K Tajima, T Watanabe.   

Abstract

The clinical features of idiopathic uveitis were compared by the seropositivity for human T-cell lymphotropic virus type I. The statistical analysis of various clinical variables disclosed that the uveitis seen in seropositive patients (93 patients) had a significantly higher incidence of floaters, vitreous opacities, retinal vasculitis, and intermediate uveitis than that in seronegative patients (222 patients) (P < .05). The odds ratios of the virus infection for these clinical manifestations were high and statistically significant, suggesting that the virus infection has a role as a risk factor for the development of these clinical manifestations. Although visual acuity at the initial examination was almost equal between the two groups, after the therapy with topical or systemic corticosteroids, or both, visual acuity in seropositive patients was much better than that in seronegative patients. The surface phenotype of peripheral lymphocytes in the two groups was compared as follows: CD4-positive T lymphocytes (P < .05), CD4/8 ratio (P < .01), and CD25-positive T lymphocytes (P < .05) were significantly higher in seropositive patients than in seronegative patients.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8352299     DOI: 10.1016/s0002-9394(14)71279-6

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  16 in total

1.  Turning a blind eye: HTLV-1-associated uveitis in Indigenous adults from Central Australia.

Authors:  Rusheng Chew; Timothy Henderson; Jaskirat Aujla; Eline Whist; Lloyd Einsiedel
Journal:  Int Ophthalmol       Date:  2017-07-28       Impact factor: 2.031

2.  Prevalence of HTLV-I-associated uveitis in the Kanto Plain, Japan.

Authors:  M Ishioka; K Goto; S Nakamura; N Watanabe; E Uchio; K Saeki; S Ohno
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1995-08       Impact factor: 3.117

Review 3.  A new era of uveitis: impact of polymerase chain reaction in intraocular inflammatory diseases.

Authors:  Manabu Mochizuki; Sunao Sugita; Koju Kamoi; Hiroshi Takase
Journal:  Jpn J Ophthalmol       Date:  2016-10-27       Impact factor: 2.447

4.  Increased number of circulating HTLV-1 infected cells in peripheral blood mononuclear cells of HTLV-1 uveitis patients: a quantitative polymerase chain reaction study.

Authors:  A Ono; M Mochizuki; K Yamaguchi; N Miyata; T Watanabe
Journal:  Br J Ophthalmol       Date:  1995-03       Impact factor: 4.638

5.  Human T lymphotropic virus type 1 uveitis after Graves' disease.

Authors:  K Yamaguchi; M Mochizuki; T Watanabe; K Yoshimura; M Shirao; S Araki; N Miyata; S Mori; T Kiyokawa; K Takatsuki
Journal:  Br J Ophthalmol       Date:  1994-03       Impact factor: 4.638

6.  Clinical features of human T lymphotropic virus type 1-associated uveitis in Hokkaido, Japan.

Authors:  Satoru Kase; Kenichi Namba; Nobuyoshi Kitaichi; Daiju Iwata; Shigeaki Ohno; Susumu Ishida
Journal:  Jpn J Ophthalmol       Date:  2013-04-23       Impact factor: 2.447

Review 7.  Human T lymphotropic virus type 1 uveitis.

Authors:  M Mochizuki; K Tajima; T Watanabe; K Yamaguchi
Journal:  Br J Ophthalmol       Date:  1994-02       Impact factor: 4.638

8.  HTLV-I associated uveitis in central Japan.

Authors:  K Goto; K Saeki; M Kurita; S Ohno
Journal:  Br J Ophthalmol       Date:  1995-11       Impact factor: 4.638

Review 9.  DNA inoculation as a novel vaccination method against human retroviruses with rheumatic disease associations.

Authors:  K E Ugen; B Wang; V Ayyavoo; M Agadjanyan; J Boyer; F Li; S Kudchodkar; J Lin; M Merva; L Fernandes
Journal:  Immunol Res       Date:  1994       Impact factor: 2.829

10.  Immunopathological mechanisms of human T cell lymphotropic virus type 1 (HTLV-I) uveitis. Detection of HTLV-I-infected T cells in the eye and their constitutive cytokine production.

Authors:  K Sagawa; M Mochizuki; K Masuoka; K Katagiri; T Katayama; T Maeda; A Tanimoto; S Sugita; T Watanabe; K Itoh
Journal:  J Clin Invest       Date:  1995-02       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.